Literature DB >> 18040893

The aldosterone to renin ratio in the evaluation of patients with incidentally detected adrenal masses.

M Tzanela1, G Effraimidis, G Effremidis, D Vassiliadi, A Szabo, N Gavalas, A Valatsou, E Botoula, N C Thalassinos.   

Abstract

Incidentally discovered adrenal masses are diagnosed with increasing frequency, especially among patients with hypertension. Thus, a reliable screening test for primary hyperaldosteronism (PA) is essential to avoid unnecessary diagnostic procedures to this population. The aim of the present study is the evaluation of aldosterone to renin ratio (ARR), using plasma renin concentration, in the diagnostic algorithm of patients with adrenal incidentaloma. A total of 123 individuals were studied: 17 patients with proven PA (age 55.5 +/- 1.4 years), 27 patients with nonfunctioning adrenal incidentaloma (age 60.3 +/- 1.8 years, 14 hypertensives and 13 normotensives) and 79 control subjects (age 58.7 +/- 1.4 years, 27 hypertensives and 52 normotensives). A receiver operating characteristic (ROC) analysis disclosed that an ARR > or =32 combines a sensitivity of 100% with a specificity of 96.2% for the diagnosis of PA. No difference in AlphaRR between hypertensive and normotensive individuals harbouring an adrenal incidentaloma and hypertensive and normotensive controls was found. Patients with adrenal incidentalomas with subtle glucocorticoid hypersecretion demonstrated similar ARR compared to patients with normal cortisol secretion. In conclusion, ARR is reliable for the exclusion of PA in patients with adrenal incidentalomas. Furthermore, subtle aldosterone hypersecretion, as indicated by increased ARR, in patients with adrenal incidentalomas is not associated with the presence of hypertension or subtle glucocorticoid hypersecretion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040893     DOI: 10.1007/s12020-007-9028-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  34 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension, congestive heart failure, and liver cirrhosis.

Authors:  P F Plouin; P Cudek; J F Arnal; T T Guyene; P Corvol
Journal:  Horm Res       Date:  1990

3.  Primary aldosteronism in normokalemic patients with adrenal incidentalomas.

Authors:  Giampaolo Bernini; Angelica Moretti; Gianfranco Argenio; Antonio Salvetti
Journal:  Eur J Endocrinol       Date:  2002-04       Impact factor: 6.664

4.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

5.  Management of the clinically inapparent adrenal mass ("incidentaloma").

Authors:  Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

6.  Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass.

Authors:  Nicole Unger; Ingo Lopez Schmidt; Christian Pitt; Martin K Walz; Thomas Philipp; Klaus Mann; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2004-04       Impact factor: 6.664

7.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 8.  The current epidemic of primary aldosteronism: causes and consequences.

Authors:  Norman M Kaplan
Journal:  J Hypertens       Date:  2004-05       Impact factor: 4.844

9.  Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.

Authors:  C Seifarth; S Trenkel; H Schobel; E G Hahn; J Hensen
Journal:  Clin Endocrinol (Oxf)       Date:  2002-10       Impact factor: 3.478

10.  A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.

Authors:  K Hiramatsu; T Yamada; Y Yukimura; I Komiya; K Ichikawa; M Ishihara; H Nagata; T Izumiyama
Journal:  Arch Intern Med       Date:  1981-11
View more
  4 in total

1.  Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division.

Authors:  Dan Ye; FengQin Dong; XunLiang Lu; Zhe Zhang; YunFei Feng; ChengJiang Li
Journal:  Endocrine       Date:  2012-01-03       Impact factor: 3.633

2.  Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis.

Authors:  Xiyue Li; Richa Goswami; Shumin Yang; Qifu Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-08-17       Impact factor: 1.636

3.  Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: a systematic review and meta-analysis.

Authors:  Hongjiao Gao; Rong Luo; Jindie Li; Haoming Tian
Journal:  Ann Transl Med       Date:  2022-06

4.  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Niki Katsiki; Konstantinos Petidis; Apostolos Kamparoudis; Panagiotis Petras; Vasiliki Georgopoulou; Stefanos Finitsis; Christodoulos Papadopoulos; Vasilios G Athyros; Michael Doumas; Asterios Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-05-02       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.